A cPLA2 inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Giripladib

Item No. 19701

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[3-[5-chloro-1-(diphenylmethyl)-2-[2-[[[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]amino]ethyl]-1H-indol-3-yl]propyl]-benzoic acid
CAS Number
865200-20-0
Synonyms
  • PLA-695
Molecular Formula
C41H36ClF3N2O4S
Formula Weight
745.3
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
Acetonitrile: Slightly Soluble: 0.1-1 mg/mlDMSO: Sparingly Soluble: 1-10 mg/ml
SMILES
OC(C(C=C1)=CC=C1CCCC2=C(CCNS(CC3=C(C(F)(F)F)C=CC=C3)(=O)=O)N(C(C4=CC=CC=C4)C5=CC=CC=C5)C6=C2C=C(Cl)C=C6)=O
InChi Code
InChI=1S/C41H36ClF3N2O4S/c42-33-22-23-37-35(26-33)34(16-9-10-28-18-20-31(21-19-28)40(48)49)38(47(37)39(29-11-3-1-4-12-29)30-13-5-2-6-14-30)24-25-46-52(50,51)27-32-15-7-8-17-36(32)41(43,44)45/h1-8,11-15,17-23,26,39,46H,9-10,16,24-25,27H2,(H,48,49)
InChi Key
NHHBNHIPCSPSHQ-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $215

    Add

    5 mg

    $538

    Add

    10 mg

    $860

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Giripladib is a cytosolic phospholipase A2 (cPLA2) inhibitor.1,2 It increases arachidonoyl-containing phosphatidylcholine levels in thrombin-stimulated isolated human platelets.1 Giripladib reduces platelet adhesion and accumulation in collagen-coated capillary tubes and inhibits thrombin- or convulxin-stimulated thromboxane B2 (TXB2) production in isolated human platelets. It reduces accumulation of PUFAs, malondialdehyde (MDA), and reactive oxygen species (ROS) in primary human vascular smooth muscle cells (VSMCs) stimulated with serum isolated from patients with chronic kidney disease (CKD) and inhibits ferroptosis in the same cells.2 Giripladib reduces atherosclerotic plaque vulnerability in an ApoE-/- mouse model of CKD.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Duvernay, M.T., Matafonov, A., Lindsley, C.W., et al. Platelet lipidomic profiling: Novel insight into cytosolic phospholipase A2α activity and its Role in human platelet activation. Biochemistry 54(36), 5578-5588 (2015).

    2. Bi, X., Zhou, J., Liu, L., et al. ECH1-deficiency-mediated polyunsaturated fatty acid accumulation promotes vascular smooth muscle cell ferroptosis and chronic-kidney-disease-associated plaque vulnerability. Research (Wash D.C.) 9, 1411 (2026).